CPT® Code 88342

Quick Reference:

• What 88342 means: Immunohistochemistry (IHC) or immunocytochemistry (ICC), per specimen; the initial single antibody stain procedure. It represents the first separately performed single-antibody stain on a given specimen; additional single-antibody stains on the same specimen are reported with 88341.
• Unit rule that drives audits: CMS NCCI policy states that only one unit of CPT 88342 may be reported per specimen. Multiple slides cut from the same specimen and stained with the same antibody do not justify multiple units of 88342.
• Specimen matters more than slide count: Medicare coverage policy expects that each stain is ordered to answer a specific diagnostic/therapeutic question, and the pathology report should identify the block/specimen, the antibody stain(s) used, and interpretive results.
• Additional stains and multiplex: Use 88341 for each additional single antibody stain on the same specimen, and use 88344 when a multiplex stain procedure is performed (multiple antibodies applied as one multiplex procedure with distinguishable results). Correct code selection is reinforced in CMS billing/coding guidance and NCCI policy.
• Component billing: 88342 may be billed globally, or split using -TC (technical component) and -26 (professional component) when applicable. Payer policies often evaluate unit limits at the code level even when split-billed.
• Coverage is documentation-driven: CMS coverage policy requires that special stains/IHC are reasonable and necessary and used to resolve a specific clinical/pathologic question. Generic statements (“IHC confirms diagnosis”) are a common denial risk when the rationale and interpretive conclusion are not clear.
• Medicare payment reference: CAP’s Medicare Physician Fee Schedule impact table provides national payment benchmarks for 88342 (global and split components) used by many organizations for budgeting and contract comparisons (rates vary by locality and contract).

CPT 88342 is the foundational code for billing the first single-antibody immunohistochemistry (IHC) or immunocytochemistry (ICC) stain performed per specimen. It is widely used across surgical pathology—tumor classification, lineage determination, site-of-origin evaluation, predictive marker workflows, and selected infectious agent detection. Despite being common, 88342 is frequently targeted in audits because reimbursement depends on strict unit logic (specimen-level counting) and because coverage is explicitly tied to medical necessity and interpretive reporting. Medicare policy and claims edits do not treat IHC as “slide-based volume billing”; rather, they expect each stain to answer a defined question, with one initial stain per specimen and additional stains coded appropriately.

1. Definition and Scope of CPT 88342

CPT 88342 describes: “Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.”

Operationally, the code represents the performance of the first single-antibody IHC/ICC stain procedure on a given specimen, including the work required to prepare and stain the slide(s) and the professional interpretation documented by the pathologist when billed globally. CMS billing and coding guidance and CMS NCCI policy emphasize that reporting is per specimen, not “per slide,” and that unit assignment must follow the per-specimen logic.

What the code pays for: From a claims and audit standpoint, 88342 is an administrative proxy for the laboratory and professional resources required to perform and interpret an IHC/ICC stain. While local laboratory processes vary (platform, antibody clone selection, retrieval conditions, controls), Medicare coverage policy focuses less on internal technical choices and more on whether the stain was reasonable and necessary to answer a diagnostic/therapeutic question, and whether the medical record supports that use with interpretive reporting.

Key boundary: CMS NCCI policy states that only one unit of CPT 88342 may be reported per specimen. If multiple different single-antibody stains are performed on that same specimen, only the first is 88342; additional single-antibody stains are 88341. This is one of the most enforced rules in IHC coding, and it drives the majority of audit findings in this area.

Practical boundary: The “specimen” concept is the controlling unit for 88342. Multiple slides, deeper levels, repeats due to technical failure, and multiple sections stained with the same antibody do not automatically create additional payable units. The coding and documentation must align to specimen-based counting and medically necessary decision-making.

2. Clinical Use Cases and Why IHC Is Ordered

IHC/ICC is ordered when routine morphology (typically H&E) does not fully resolve a diagnostic or clinically actionable question. Medicare’s coverage framework expects that special stains and immunohistochemical stains are used to answer a specific question and influence diagnosis, staging, prognosis, or treatment selection.

• Tumor classification and lineage determination:

IHC is frequently used to distinguish broad categories (e.g., carcinoma vs lymphoma vs melanoma vs sarcoma) and to define lineage using marker panels. The coding implication is predictable: the first single-antibody stain is 88342 per specimen, and subsequent single-antibody stains are 88341 when performed on that same specimen to complete the diagnostic work-up.

• Site-of-origin evaluation (metastatic disease or unknown primary):

Tissue-of-origin marker strategies are common in metastatic tumors (e.g., lung/thyroid-associated markers, gastrointestinal markers, urothelial markers). Coverage rationales are typically strongest when the report explicitly states the clinical question (e.g., “determine primary site”) and connects the staining pattern to the final interpretation.

• Predictive biomarker workflows:

While many predictive assays have their own testing paradigms, IHC remains a frequent pathway for certain markers. The coding risk increases when laboratories attempt to bill based on the number of slides or repeats rather than the number of medically necessary stains per specimen, which is why CMS policies stress per-specimen counting and clear interpretive reporting.

• Selected infectious agent detection in tissue:

In certain contexts, immunostains are used to detect organisms or viral antigens in tissue. The defensibility of coverage depends on the report identifying the suspected organism question (e.g., “evaluate for CMV”) and describing the interpretive result and diagnostic implication.

• Clarifying ambiguous morphology (limited material, crush artifact, necrosis):

Medicare’s medical necessity standard is typically met when the stain clarifies diagnosis in cases where morphology is insufficient. Again, the documentation must make that logic explicit, especially when multiple stains are used.

3. CMS Billing Rules: Specimen-Based Units, NCCI, and Coverage

3.1 Coverage principle: “reasonable and necessary” and question-driven ordering

Medicare coverage policy for special stains and immunohistochemical stains requires that each stain be reasonably and medically necessary to resolve a diagnostic or therapeutic question. The policy expectation is not merely that a stain was performed, but that it was performed for a defined reason and that results were interpreted and documented in a way that affects the pathology conclusion and/or patient management.

CMS billing/coding guidance reinforces the concept that H&E staining is part of the baseline pathology service and is not separately billed as a special stain service; special stains/IHC are complementary tools used when the routine evaluation does not answer the question. This conceptual framing matters because payers often scrutinize “standing panel” behavior—automatic stain ordering without case-specific justification.

3.2 Unit logic: one initial stain per specimen

The most important unit rule is explicitly stated in CMS NCCI policy: only one unit of CPT 88342 may be reported per specimen. If additional different single-antibody stains are performed on the same specimen, they are not additional 88342 units; they are reported with 88341 (each additional single antibody stain).

This policy has a practical operational interpretation: specimen-based counting discourages “slide multiplication” and aligns payment with the conceptual service (the initial stain procedure per specimen), rather than the number of physical slides cut. Laboratories should therefore maintain internal tracking at the specimen/block level for each antibody and link that tracking to billing logic.

3.3 Medicare billing/coding guidance: alignment of code choice and narrative reporting

CMS billing/coding guidance associated with the LCD provides practical statements about how stains should be approached in relation to routine evaluation and how the documentation should support the necessity of additional stains. In operational audits, the pathology report often becomes the central evidence. If the report fails to specify what was stained, why it was stained, and what the stain showed, the claim becomes vulnerable even if the technical work was performed appropriately.

Audit trigger: Claims are commonly challenged when the record appears to show “routine paneling” rather than case-driven stain selection. The strongest defense is a report that states the diagnostic question and uses the staining pattern to justify the final interpretive conclusion.

4. Professional vs Technical Billing (26/TC) and Common Pitfalls

CPT 88342 may be billed as a global service or split into its technical and professional components using modifiers -TC and -26 when the billing arrangement supports component reporting. Many payer policies recognize this split billing structure and evaluate utilization limits at the code level (i.e., a TC and a 26 together functionally represent one global unit for many limit calculations).

• Technical component (-TC): Laboratory performance of the stain procedure (processing, staining workflow, reagents/controls, technical labor).
• Professional component (-26): Pathologist interpretation and reporting (the signed diagnostic statement reflecting stain results and their meaning).

Common split-billing pitfall: Component billing must reflect actual service allocation. If the laboratory and the pathologist are part of the same billing entity and the global service is reported, separate TC and 26 lines can create duplicate payment risk or payer confusion. Conversely, billing only 26 without clear evidence of where the technical work was performed can also trigger documentation requests.

Unit accounting remains specimen-based: Component billing does not change the fundamental NCCI rule: only one 88342 per specimen. If a case has one initial antibody stain and multiple additional stains, the coding structure remains 88342 + 88341(s) (or 88344 when multiplex applies), regardless of whether billing is global or split.

5. Related Codes: 88341, 88344, and When to Use Them

Correct reporting of 88342 requires correct use of the companion codes used in IHC workflows. CMS billing/coding guidance and NCCI policy are the strongest anchors for these distinctions.

• 88341 (each additional single antibody stain):

Used for each additional single-antibody stain procedure on the same specimen after the initial stain has been reported with 88342. Misreporting multiple 88342 units instead of 88342 + 88341 is one of the most common and most visible IHC coding errors.

• 88344 (multiplex antibody stain procedure):

Used when a multiplex stain procedure is performed (multiple antibodies applied within a multiplex process where results are distinguishable). A frequent error is billing separate single-antibody codes when the lab actually performed a multiplex procedure; the code choice must reflect the laboratory method and clinical reporting.

Practical rule: Do not code based on what is “most reimbursable.” Code based on what was done and documented. In IHC, payers commonly validate claims against method (single vs multiplex), specimen-based unit logic, and the narrative interpretation in the pathology report.

6. Documentation Standards That Support Medical Necessity

Documentation is the core compliance pillar for 88342 because Medicare’s coverage policy requires stains to be medically necessary and to resolve a specific question. The pathology report is expected to identify (1) what was stained, (2) why it was stained, (3) what the stain showed, and (4) how that result informed the diagnostic interpretation.

6.1 Minimum documentation elements (audit-defensible)

• Specimen/block identification: Clear identification of the specimen and (when relevant) the block or part (e.g., “Block A1”).
• Antibody stain(s) performed: Name the marker(s) used, preferably in a structured addendum or within the microscopic description.
• Clinical/diagnostic question: A short statement of purpose (e.g., “to evaluate epithelial differentiation,” “to assess lymphoid lineage,” “to evaluate primary site”). Medicare policy expects stains to resolve a specific question.
• Interpretive result and pattern: Not just “positive/negative,” but the relevant pattern (e.g., tumor cell staining vs background; nuclear vs cytoplasmic; diffuse vs focal) when clinically meaningful.
• Diagnostic conclusion: Explicit linkage between the stain pattern and the diagnostic conclusion or differential resolution.

6.2 Avoiding vague language that fails medical necessity review

A common denial vulnerability is documentation that does not demonstrate why the stain was needed or how it affected interpretation. Generic statements (e.g., “IHC confirms diagnosis”) may fail to show the stain’s necessity. Medicare policy emphasizes that stains should address a specific question and be integral to diagnosis/management.

6.3 Relationship to H&E and workflow logic

CMS billing/coding guidance emphasizes that H&E staining is part of routine pathology evaluation and not separately billed as a special stain service. From a defensibility standpoint, the record should reflect that IHC was ordered because the routine evaluation required further clarification—this can be explicit (“morphology alone is insufficient”) or implicit through differential discussion that the stains resolve.

7. Payer Operations: Unit Edits, Utilization Limits, and Practical Claim Behavior

While Medicare policy provides the most authoritative baseline (coverage via LCD and unit logic via NCCI), payers may apply additional operational limits such as maximum units per date or per case. These limits often mirror specimen-based logic and are typically justified as utilization controls. Examples from commercial and Medicaid policies demonstrate how payers operationalize specimen-based counting and apply date-of-service limits for 88342 and related codes.

• Commercial payer unit limits: Some commercial policies describe maximum specimens or units per date for 88342 and companion codes, typically consistent with “one unit per specimen” logic.
• Medicaid program guidance: State Medicaid (or contracted plan) guidance may include routine maximums per date of service and clarify component billing treatment and unit counting.
• Why this matters operationally: Even when the underlying medical necessity is strong, claims can deny if the billed unit volume exceeds payer edits without documentation or without an appropriate appeal narrative that ties each stain to a distinct, necessary question.

Operational best practice: Maintain an internal “stain log” mapped to specimen/block and antibody, and ensure the pathology report supports the stain logic. This aligns billing to CMS NCCI specimen-based rules and supports appeals when payer unit edits trigger requests.

8. Comparison Table: 88342 vs 88341 vs 88344

9. Real-World Scenarios (Audit-Defensible Patterns)

Scenario 1: Single stain resolves the question

Clinical context: Morphology suggests a differential where one marker can confirm lineage.

Work performed: One single-antibody stain is performed on specimen A.

Coding: 88342 (one unit for specimen A).

Documentation tip: State the question (e.g., “evaluate epithelial differentiation”), report the stain pattern, and link to the diagnostic conclusion. Medicare coverage expects question-driven stains with interpretive reporting.

Scenario 2: Two distinct antibodies on the same specimen

Clinical context: Tumor classification requires a two-marker approach.

Work performed: Two different single-antibody stains on specimen A.

Coding: 88342 (initial) + 88341 (each additional single antibody stain on the same specimen).

Why this matters: CMS NCCI policy allows only one 88342 per specimen; additional stains must be coded as 88341.

Scenario 3: Multiple slides with the same antibody (do not multiply units)

Clinical context: Limited tumor on initial level; deeper levels are cut and stained with the same antibody to improve evaluation.

Work performed: Same single antibody applied to multiple slides from specimen A.

Coding: 88342 (still one unit for the initial single-antibody stain procedure per specimen).

Compliance rationale: Specimen-based unit counting is required; NCCI policy prohibits multiple 88342 units per specimen.

Scenario 4: Multiplex method used

Clinical context: Laboratory performs a multiplex antibody stain procedure with distinguishable results to address a diagnostic question.

Work performed: Multiplex stain procedure on specimen A.

Coding: 88344 for the multiplex stain procedure (rather than multiple single stain codes), consistent with CMS coding guidance describing multiplex reporting.

Scenario 5: Multiple specimens in the same case

Clinical context: Separate specimens (e.g., parts A and B) each require IHC to answer distinct diagnostic questions.

Work performed: One single-antibody stain performed on each specimen.

Coding: One unit of 88342 per specimen (e.g., 88342 x 2 for specimens A and B), with additional stains per specimen coded as 88341 as appropriate.

Operational note: Some payers apply routine per-date unit caps; when exceeded legitimately, documentation should clearly support why each specimen required staining and how each stain affected interpretation.

10. Reimbursement Notes and Benchmarking

Medicare payment rates change annually and are geographically adjusted. For planning and benchmarking, many pathology organizations use CAP’s Medicare Physician Fee Schedule impact tables as an accessible summary of national, non-facility payment benchmarks for codes such as 88342 and related staining services. These tables include global and component values (e.g., 88342 global and 88342 with modifiers 26 and TC).

Practical payment perspective: Even when reimbursement is favorable, the financial risk of recoupment is driven by compliance and documentation failures—especially miscounting units per specimen, misclassifying multiplex work, and insufficient interpretive narrative that does not show medical necessity. CMS coverage policy and NCCI specimen-based rules should be treated as the primary compliance anchors.

Sources

• Charles Fiegl, “CAP proposals on IHC… accepted for Medicare in ’15,” CAP Today, Nov 2014. Background discussion that includes CPT-related context and historical policy framing referenced by some labs; use CMS policy documents as the primary compliance anchor.
• CMS LCD L35922 “Special Stains and Immunohistochemical Stains,” effective 6/30/2024. Medicare coverage policy emphasizing medical necessity and documentation expectations for special stains and IHC.
• CMS A56838 “Billing & Coding: Lab: Special Histochemical and Immunohistochemical Stains,” published 07/14/2024. CMS billing/coding guidance that complements LCD L35922 and reinforces reporting expectations and baseline pathology concepts (including H&E as routine).
• CMS NCCI Policy Manual (Rev. 2/28/2025). Primary CMS policy source for specimen-based unit logic (including the “one unit of 88342 per specimen” rule) and related coding principles.
• EmblemHealth Lab Benefit Program – IHC Reimbursement Policy (issued 2024, effective 2026). Example of commercial payer operational limits and coding logic applied to 88342/88341/88344; useful for payer-specific edit expectations.
• BCBS Oklahoma (CPCP) – Immunohistochemistry policy (March 2024). Commercial payer policy example that reflects specimen-based unit logic and utilization controls.
• Louisiana Medicaid (AmeriHealth Caritas) – IHC Billing Guidelines (2023). Medicaid program guidance example including unit logic and component billing considerations used by contracted plans.
• College of American Pathologists – Medicare PFS Final 2025 Impact Table (Nov 2024). CAP-prepared summary table used for Medicare payment benchmarking (global and component amounts) for pathology codes including 88342.